September 7th 2020
By Skylar Jeremias
This summer, The Center for Biosimilars® interviewed several experts for their opinions on the current need for biosimilars and how companies are working to overcome barriers to uptake. Here are some highlights.
September 3rd 2020
By Tony Hagen
Multiple studies indicate the nocebo effect is particularly influential in the treatment of inflammatory bowel disease (IBD), according to an opinion piece.
Bio-Thera said it has begun testing the safety its ustekinumab biosimilar in healthy volunteers.
September 1st 2020
A look at efforts biosimilar manufacturers are taking to develop treatments for coronavirus disease 2019 (COVID-19).
August 31st 2020
By Deana Ferreri, PhD
Health technology tssessments play an important role in building confidence for use of biosimilars, yet very few meet criteria for thoroughness.
For all intents and purposes, Semglee is a biosimilar insulin, but official biosimilar status is needed to clinch the marketing aspect.
August 27th 2020
Two decades of using anti–tumor necrosis factor (TNF) drugs in inflammatory bowel disease (IBD) have answered some questions and left others unanswered.
August 18th 2020
By The Center for Biosimilars
Ali Mcbride, PharmD, MS, BCOP, is taking a lead role in promoting the use and understanding of biosimilars in oncology.
August 15th 2020
There has been an outpouring of advocacy tugging biosimilars into the marketplace, and market share of these lower-cost drugs has increased.
August 14th 2020
Allowing pharmacists to independently fill prescriptions with biosimilars can offer community oncology practices a way to cut costs and increase access to cancer care for patients, according to Lucy Langer, MD.